Article Text

Download PDFPDF
Case of Guillain-Barré syndrome following COVID-19 vaccine
  1. Tanveer Hasan,
  2. Mustafizur Khan,
  3. Farhin Khan and
  4. Ghanim Hamza
  1. East Kent Hospitals University NHS Foundation Trust, Canterbury, UK
  1. Correspondence to Dr Tanveer Hasan; tanveer_hasan316{at}live.com

Abstract

Guillain-Barré syndrome (GBS) is a rare immune-mediated disorder of the peripheral nerves. Although its cause is not fully understood, the syndrome often follows infection with a virus or bacteria, although in rare occasions, vaccination may precede GBS. We describe a case of a 62-year-old woman who presented with paraesthesia and progressive weakness of both lower limbs over 3 days. Clinical examination and investigation findings including lumbar puncture and nerve conduction studies were consistent with the diagnosis of GBS. She had no history of either diarrhoea or respiratory tract infections preceding her presentation. However, she had her first intramuscular dose of the Oxford/AstraZeneca COVID-19 vaccine 11 days prior to her presentation. Although no direct link could be ascertained, the purpose of this report is to highlight the incidence and consider this issue while evaluating any case of GBS in the light of the current pandemic and vaccination programme.

  • COVID-19
  • immunological products and vaccines
  • vaccination/immunisation
  • peripheral nerve disease

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors TH and MK: took the initiative to write this case report, having been involved in the patient’s care directly. TH: Planning and designing. MK and FK: wrote the introduction, case presentation, investigation and treatment sections. They collected the data including investigation findings after taking consent from the patient. TH: involved in writing the differentials, discussion and learning points. TH: edited major portions of other sections. All three of them were involved in proof reading and making corrections. Following this, TH formatted the case report and images according to BMJ Case Reports Journal requirements. GH: responsible for supervising the project. He made valuable suggestions and modifications.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.